Seracare Life Sciences (SRLS) 10-Q 2008 Q2 Quarterly report

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2008

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from            to          

Commission file number: 0-33045

SeraCare Life Sciences, Inc.

(Exact name of registrant as specified in its charter)

DE	33-0056054
(State or other jurisdiction	(I.R.S. Employer
of incorporation or organization)	Identification No.)
37 Birch Street
Milford, MA	01757
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (508) 244-6400

     Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yesþ Noo

     Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filero	Accelerated filero	Non-accelerated filerþ	Smaller reporting companyo
		(Do not check if a smaller reporting company)

     Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yeso
Noþ

     Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yesþ Noo

     The number of shares of common stock outstanding as of April 30, 2008 was 18,563,476.

TABLE OF CONTENTS

	Page
PART I: FINANCIAL INFORMATION
Item 1. Financial Statements		2
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		13
Item 3. Quantitative and Qualitative Disclosures About Market Risk		17
Item 4. Controls and Procedures		17
PART II: OTHER INFORMATION
Item 1. Legal Proceedings		18
Item 1A. Risk Factors		18
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		18
Item 4. Submission of Matters to a Vote of Securities Holders		18
Item 6. Exhibits		19
EX-10.1 Amended and Restated 2001 Stock Incentive Plan
EX-31.1 Sarbanes-Oxley Act Section 302 Certification of Susan L.N. Vogt.
EX-31.2 Sarbanes-Oxley Act Section 302 Certification of Gregory A. Gould.
EX-32.1 Sarbanes-Oxley Act Section 906 Certification of Susan L.N. Vogt and Gregory A. Gould.

PART I: FINANCIAL INFORMATION

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

     We caution you that this document contains disclosures that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about SeraCare Life Sciences, Inc. (“SeraCare” or the “Company”). All statements regarding our expected future financial position, results of operations, cash flows, dividends, financing plans, business strategy, budget, projected costs or cost savings, capital expenditures, competitive positions, growth opportunities for existing products or products under development, plans and objectives of management for future operations and markets for stock are forward-looking statements. In addition, forward-looking statements include statements in which we use words such as “expect,” “believe,” “anticipate,” “intend,” or similar expressions. Although we believe the expectations reflected in such forward-looking statements are based on reasonable assumptions, we cannot assure you that these expectations will prove to have been correct, and actual results may differ materially from those reflected in the forward-looking statements. Factors that could cause our actual results to differ from the expectations reflected in the forward-looking statements in this document include those set forth in “Risk Factors” in Part II, Item 1A. Many of these factors are beyond our ability to control or predict.

- 1 -

Item 1. Financial Statements

SERACARE LIFE SCIENCES, INC.

STATEMENTS OF OPERATIONS — UNAUDITED

	For the three months ended						For the six months ended
	March 31,						March 31,
	2008			2007			2008			2007
Revenue	$	12,530,143		$	13,989,309		$	25,156,462		$	23,899,681
Cost of revenue		7,817,189			10,657,971			16,345,025			18,097,959
Gross profit		4,712,954			3,331,338			8,811,437			5,801,722
Research and development expense		416,453			107,994			787,629			180,981
Selling, general and administrative expenses		4,113,270			3,379,540			7,831,481			6,748,581
Reorganization items		396,184			3,667,159			1,011,990			4,863,659
Operating loss		(212,953	)		(3,823,355	)		(819,663	)		(5,991,499	)
Interest expense		(94,638	)		(197,428	)		(200,071	)		(440,648	)
Interest expense, related parties		—			(108,889	)		—			(248,889	)
Other income, net		3,040			28,782			49,926			84,499
Loss before income taxes		(304,551	)		(4,100,890	)		(969,808	)		(6,596,537	)
Income taxes		26,100			24,003			27,900			38,610
Loss from continuing operations		(330,651	)		(4,124,893	)		(997,708	)		(6,635,147	)
Income (loss) from discontinued operations, net of income tax		—			207,717			—			(92,480	)
Net loss	$	(330,651	)	$	(3,917,176	)	$	(997,708	)	$	(6,727,627	)
Basic and diluted net income (loss) per common share
Continuing operations	$	(0.02	)	$	(0.29	)	$	(0.05	)	$	(0.46	)
Discontinued operations		—			0.02			—			(0.01	)
Net loss	$	(0.02	)	$	(0.27	)	$	(0.05	)	$	(0.47	)
Weighted average shares outstanding
Basic and diluted		18,561,239			14,282,948			18,559,966			14,282,948

See accompanying notes to financial statements.

- 2 -

SERACARE LIFE SCIENCES, INC.

BALANCE SHEETS — UNAUDITED

	As of			As of
	March 31,			September 30,
	2008			2007
ASSETS
Current assets
Cash and cash equivalents	$	5,989,308		$	9,523,950
Accounts receivable, less allowance for doubtful accounts of $245,000 and $175,000 as of March 31, 2008 and September 30, 2007, respectively		7,943,034			6,590,602
Taxes receivable		1,476,016			1,726,386
Inventory		10,980,200			7,316,515
Prepaid expenses and other current assets		424,414			333,305
Total current assets		26,812,972			25,490,758
Property and equipment, net		4,544,653			4,245,716
Assets held for sale		1,914,330			—
Goodwill		27,362,559			27,362,559
Other intangible assets		314,237			446,489
Other assets		694,225			894,223
Total assets	$	61,642,976		$	58,439,745
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable	$	4,470,878		$	2,201,256
Prepetition liabilities		136,247			198,612
Accrued expenses		2,697,039			2,818,700
Current portion of long term debt		213,501			187,771
Total current liabilities		7,517,665			5,406,339
Long-term debt		1,989,846			2,111,368
Other liabilities		1,685,700			397,544
Total liabilities		11,193,211			7,915,251
Commitments
Stockholders’ equity
Preferred stock, no par value, 5,000,000 shares authorized; no shares issued or outstanding		—			—
Common stock, $.001 par value, 35,000,000 shares authorized, 18,561,396 and 18,557,948 shares issued and outstanding as of March 31, 2008 and September 30, 2007, respectively		18,561			18,558
Additional paid-in capital		100,659,770			99,736,794
Retained earnings (deficit)		(50,228,566	)		(49,230,858	)
Total stockholders’ equity		50,449,765			50,524,494
Total liabilities and stockholders’ equity	$	61,642,976		$	58,439,745

See accompanying notes to financial statements.

- 3 -

SERACARE LIFE SCIENCES, INC.

STATEMENTS OF CASH FLOWS — UNAUDITED

	For the six months ended
	March 31,
	2008			2007
Cash flows from operating activities:
Net loss	$	(997,708	)	$	(6,727,627	)
Adjustments to reconcile net loss to cash provided by (used in) operating activities:
Depreciation and amortization		654,308			690,674
Amortization of deferred financing expenses		89,938			—
Bad debt expense		47,614			631
Write-down of inventory		930,324			523,920
Loss on disposal of fixed assets		11,691			—
Gain on disposition of certain assets of Genomics Collaborative division		—			(791,661	)
Stock based compensation		922,979			1,102,169
(Increase) decrease from changes:
Accounts receivable		(1,400,046	)		239,676
Taxes receivable		250,370			38,610
Inventory		(4,594,009	)		(861,892	)
Prepaid expenses and other current assets		(91,109	)		226,634
Other assets		110,060			135,000
Increase (decrease) from changes:
Accounts payable		2,269,622			905,129
Prepetition liabilities		(62,365	)		2,267,300
Accrued expenses and other liabilities		(40,243	)		1,080,668
Net cash used in operating activities		(1,898,574	)		(1,170,769	)
Cash flows from investing activities:
Purchases of property and equipment		(2,747,014	)		(233,024	)
Proceeds from the disposition of certain assets of Genomics Collaborative division		—			2,000,000
Proceeds from landlord for leasehold improvements		1,206,738			—
Net cash provided by (used in) investing activities		(1,540,276	)		1,766,976
Cash flows from financing activities:
Repayments of long-term debt		(95,792	)		(4,561,207	)
Deferred financing expenses		—			(80,000	)
Rights Offering issuance costs		—			(601,484	)
Net cash used in financing activities		(95,792	)		(5,242,691	)
Net decrease in cash and cash equivalents		(3,534,642	)		(4,646,484	)
Cash and cash equivalents,beginning of period		9,523,950			13,560,768
Cash and cash equivalents,end of period	$	5,989,308		$	8,914,284

See accompanying notes to financial statements.

- 4 -

SERACARE LIFE SCIENCES, INC.

NOTES TO FINANCIAL STATEMENTS

1. Basis of Presentation

     The unaudited condensed financial statements of SeraCare Life Sciences, Inc. (“SeraCare” or the “Company”) for the six months ended March 31, 2008 and 2007 presented herein have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission for quarterly reports on Form 10-Q. Certain information and footnote disclosures normally included in financial statements prepared in accordance with United States generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. In addition, the September 30, 2007 unaudited condensed Balance Sheet was derived from the audited financial statements, but does not include all disclosures required by GAAP. These financial statements should be read in conjunction with the audited financial statements for the year ended September 30, 2007 and the notes thereto included in the Company’s Annual Report on Form 10-K. The accounting policies used in preparing these unaudited condensed financial statements are materially consistent with those described in the audited September 30, 2007 financial statements.

     The financial information in this Report reflects, in the opinion of management, all adjustments of a normal recurring nature necessary to present fairly the results for the interim period. Quarterly operating results are not necessarily indicative of the results that may be expected for other interim periods or the year ending September 30, 2008.

     The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, as of the date of the financial statements, and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. Judgments and estimates of uncertainties are required in applying the Company’s accounting policies in many areas. Following are some of the areas requiring significant judgments and estimates: revenue recognition, accounts receivable, inventory, cash flow and valuation assumptions in performing asset impairment tests of long-lived assets, income taxes, and stock-based compensation value.

2. Recent Accounting Pronouncements

SFAS No. 157, “Fair Value Measurements”

     SFAS Statement No. 157, “Fair Value Measurements” (“SFAS 157”), has been issued by the Financial Accounting Standards Board (the “FASB”). This new standard provides guidance for using fair value to measure assets and liabilities. SFAS 157 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value but does not expand the use of fair value in any new circumstances. Currently, over 40 accounting standards within GAAP require (or permit) entities to measure assets and liabilities at fair value. The standard clarifies that for items that are not actively traded, such as certain kinds of derivatives, fair value should reflect SFAS price in a transaction with a market participant, including an adjustment for risk, not just the company’s mark-to-model value. SFAS 157 also requires expanded disclosure of the effect on earnings for items measured using unobservable data. Under SFAS 157, fair value refers to the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts. In this standard, the FASB clarifies the principle that fair value should be based on the assumptions market participants would use when pricing the asset or liability. In support of this principle, SFAS 157 establishes a fair value hierarchy that prioritizes the information used to develop those assumptions. The fair value hierarchy gives the highest priority to quoted prices in active markets and the lowest priority to unobservable data, for example, the reporting entity’s own data. Under the standard, fair value measurements would be separately disclosed by level within the fair value hierarchy.

     The FASB agreed to defer the effective date of SFAS 157 for all nonfinancial assets and liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis. The FASB again rejected the proposal of a full-one year deferral of the effective date of SFAS 157. SFAS 157 was issued in September 2006, and is effective for financial statements issued for fiscal years beginning after November 15, 2007 and interim periods within those fiscal years. Accordingly, the Company will adopt this statement on October 1, 2008. The Company is currently assessing the impact of this statement.

SFAS No. 141 (Revised 2007), “Business Combinations”

     On December 4, 2007, the FASB issued SFAS No. 141 (Revised 2007), “Business Combinations” (“SFAS 141R”).Under SFAS 141R, an acquiring entity will be required to recognize all the assets acquired and liabilities assumed in a transaction at the acquisition-date fair value with limited exceptions. SFAS 141R will change the accounting treatment for certain specific items, including:

• acquisition costs will be generally expensed as incurred;

- 5 -

• noncontrolling interests will be valued at fair value at the acquisition date;

• acquired contingent liabilities will be recorded at fair value at the acquisition date and subsequently measured at either the higher of such amount or the amount determined under existing guidance for non-acquired contingencies;

• in-process research and development will be recorded at fair value as an indefinite-lived intangible asset at the acquisition date until the completion or abandonment of the associated research and development efforts;

• restructuring costs associated with a business combination will be generally expensed subsequent to the acquisition date; and

• changes in deferred tax asset valuation allowances and income tax uncertainties after the acquisition date generally will affect income tax expense.

     SFAS 141R also includes a substantial number of new disclosure requirements. SFAS 141R applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. Earlier adoption is prohibited. Accordingly, the Company will adopt this statement on October 1, 2009. The Company is currently assessing the impact of this statement.

SFAS No. 160, “Noncontrolling Interests in Consolidated Financial Statements — An Amendment of ARB No. 51”

     On December 4, 2007, the FASB issued SFAS No. 160, “Noncontrolling Interests in Consolidated Financial Statements — An Amendment of ARB No. 51” (“SFAS 160”). SFAS 160 establishes new accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. Specifically, this statement requires the recognition of a noncontrolling interest (minority interest) as equity in the consolidated financial statements and separate from the parent’s equity. The amount of net income attributable to the noncontrolling interest will be included in consolidated net income on the face of the income statement. SFAS 160 clarifies that changes in a parent’s ownership interest in a subsidiary that do not result in deconsolidation are equity transactions if the parent retains its controlling financial interest. In addition, this statement requires that a parent recognize a gain or loss in net income when a subsidiary is deconsolidated. Such gain or loss will be measured using the fair value of the noncontrolling equity investment on the deconsolidation date. SFAS 160 also includes expanded disclosure requirements regarding the interests of the parent and its noncontrolling interest. SFAS 160 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008. Earlier adoption is prohibited. Accordingly, the Company will adopt this statement on October 1, 2009. The Company is currently assessing the impact of this statement.

FIN No. 48, “Accounting for Uncertainty in Income Taxes — An Interpretation of FASB Statement No. 109”

     FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes — An Interpretation of FASB Statement No. 109”(“FIN 48”) was issued on July 13, 2006. FIN 48 clarifies the accounting for uncertainty in income taxes recognized in a company’s financial statements in accordance with FASB Statement No. 109,Accounting for Income Taxes.FIN 48 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The new FASB standard also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.

     The provisions of FIN 48 are effective for fiscal years beginning after December 15, 2006. The provisions of FIN 48 are to be applied to all tax positions upon initial adoption of this standard. Only tax positions that meet the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized upon adoption of FIN 48. The cumulative effect of applying the provisions of FIN 48 should be reported as an adjustment to the opening balance of retained earnings (or other appropriate components of equity or net assets in the statement of financial position) for that fiscal year. The Company adopted FIN 48 on October 1, 2007. FIN 48 did not have a material effect on the Company’s condensed financial position, results of operations or cash flows.

3. Reorganization

     Reorganization items include legal, accounting and other professional fees related to the Company’s bankruptcy proceedings, reorganization, litigation and efforts to become compliant with the Securities and Exchange Commission (“SEC”). These expenses totaled $0.4 million and $3.7 million in the three months ended March 31, 2008 and 2007, respectively. For the six months ended March 31, 2008 and 2007, reorganization items totaled $1.0 million and $4.9 million, respectively.

4. Inventory

     Inventory consists primarily of human blood plasma and products derived from human blood plasma. Inventory is carried at specifically identified cost and assessed periodically to ensure it is valued at the lower of cost or market. The Company

- 6 -

reviews inventory periodically for impairment based upon factors related to usability, age and fair market value and provides a reserve where necessary to ensure the inventory is appropriately valued. A provision has been made to reduce excess and not readily marketable inventories to their estimated net realizable value.

     Inventory consists of the following:

	March 31,			September 30,
	2008			2007
Raw materials and supplies	$	1,905,598		$	1,244,399
Work-in process		1,738,958			1,126,113
Finished goods		10,073,335			7,156,639
Gross inventory		13,717,891			9,527,151
Reserve for obsolete inventory		(2,737,691	)		(2,210,636	)
Net inventory	$	10,980,200		$	7,316,515

5. Commitments and Contingencies

Chapter 11 Bankruptcy

     On March 22, 2006, SeraCare Life Sciences, Inc., a California corporation, filed a voluntary petition for reorganization under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of California (the “Bankruptcy Court”). On February 21, 2007, the Bankruptcy Court entered an order confirming the Joint Plan of Reorganization (the “Plan of Reorganization”). The Plan of Reorganization became effective on May 17, 2007, on which date the provisions of the Plan of Reorganization became operative and the transactions contemplated by the Plan of Reorganization were consummated.

Shareholder Litigation

     The Company and certain of its former officers and directors and one of its current directors were named in a number of federal securities class action lawsuits as well as federal and state derivative class action lawsuits. Beginning on December 22, 2005, the first of seven shareholder class action complaints was filed in the United States District Court for the Southern District of California. Those cases were subsequently consolidated under the captionIn re SeraCare Life Sciences, Inc. Securities Litigation, Master File No. C-05-2335-H. On September 4, 2007, the United States District Court for the Southern District of California approved the motion for final settlement of the federal class actions and entered an order of settlement and final judgment dismissing with prejudice the claims. There were no objections to the final settlement. Shareholders owning a nonmaterial number of shares opted out of the final settlement. Pursuant to the settlement, $4.4 million was provided pursuant to the Company’s insurance policy with Carolina Casualty, of which $3.0 million was awarded to the plaintiffs, $0.5 million was reserved to cover ongoing legal expenses for directors and officers related to the SEC and Department of Justice (“DOJ”) investigation (described below) and the remaining $0.9 million was reserved to cover the defendants’ previously incurred legal expenses. All of the defendants in the lawsuit settled with the Company by waiving any future indemnification with respect to the DOJ investigation and/or other matters in exchange for being released by the Company with respect to any derivative action.

Department of Justice/Securities and Exchange Commission

     In the first half of 2006, the U.S. Attorney’s Office for the Southern District of California issued grand jury subpoenas to the Company and to certain former officers and directors requesting the production of certain documents. At about the same time, the Company learned that the staff of the SEC, Division of Enforcement was also conducting an investigation of the events that led the Company to bankruptcy. The SEC issued five subpoenas to the Company for the production of documents throughout 2006 and made requests for additional information in 2007. Certain current and former employees also provided testimony as part of the investigation. The Company is cooperating fully with the requests of these agencies.

CTL Analyzers, LLC

     In July 2006, CTL Analyzers, LLC (“CTL”), a medical technology company that makes devices to measure cellular immune responses, asserted a claim for breach of contract under the Company’s Plan of Reorganization in the Bankruptcy Court. The Company has objected to such claim. The total amount claimed by CTL is $2.4 million, although the Company believes that its liability is significantly lower. The Company is in continued negotiations with CTL, which are anticipated to result in a resolution (the precise amount of which is being negotiated) to be returned to the claimant in full satisfaction of the claim asserted against the Company. A hearing is scheduled for June 2008 in the Bankruptcy Court. The Company does not expect any settlement to have a material impact on the financial statements.

- 7 -

     In addition, the Company is involved from time to time in litigation incidental to the conduct of the Company’s business, but except as noted in the prior paragraph, the Company is not currently a party to any material lawsuit or proceeding.

6. Leases

     On October 1, 2007, the Company entered into a lease agreement pursuant to which the Company is leasing an additional 23,000 square feet for a total of approximately 60,000 rentable square feet in three buildings in a business park in Milford, Massachusetts. The initial term of the lease agreement is approximately ten years, which may be extended by the Company for three successive extension terms of five years each, subject to certain conditions set forth in the lease agreement. The new campus expands upon space currently occupied by the Company at the Milford site. Renovations on the buildings in the new Milford facility began in early October 2007. In January 2008, the Company moved its headquarters from its West Bridgewater, Massachusetts facility to its Milford facility and anticipates moving the manufacturing operations from West Bridgewater to Milford by the end of fiscal 2008. The Milford facility will house SeraCare’s entire Massachusetts operations of approximately 140 employees, including the Company’s corporate headquarters. The renovations to the Milford facility have generated an increase in capital expenditures related to leasehold improvements. The Company has been reimbursed $1.2 million by the landlord and has recorded a deferred lease liability which will be recognized over the term of the lease using the straight-line method. The Company is also accounting for the lease expense using the straight-line method.

     In addition, the Company is currently leasing properties in Frederick, Maryland and Gaithersburg, Maryland. These operating leases expire July 2015 and October 2017, respectively, and currently consist of approximately 65,000 square feet and 36,000 square feet, respectively. These properties include laboratories, refrigerated storage facilities and administrative offices. These leases are accounted for as operating leases using the straight-line method. The Company also leases various equipment under capital leases.

     Future minimum rental obligations under the aforementioned lease agreements are as follows:

	Capital			Operating		Total
	Leases			Leases		Leases
Fiscal years ended September 30, except where noted
2008 (April 1, 2008 through September 30, 2008)	$	53,492		$	1,132,201	$	1,185,693
2009		106,984			2,304,743		2,411,727
2010		34,439			2,403,099		2,437,538
2011		19,930			2,538,307		2,558,237
2012		12,766			2,619,312		2,632,078
Thereafter		—			12,273,842		12,273,842
Total Minimum Lease Payments		227,611		$	23,271,504	$	23,499,115
Less: amounts representing interest		(24,194	)
Present value of future minimum capital lease payments	$	203,417

7. Assets Held For Sale

     On October 1, 2007, the Company signed a lease agreement with the intention of moving its headquarters to its Milford facility. As a result, the Company began marketing the West Bridgewater facility and land for sale. The net book value of these assets is $1.9 million as of March 31, 2008.

- 8 -

8. Long-Term Debt

     Long-term debt consists of the following:

	March 31,			September 30,
	2008			2007
Real property mortgage note	$	1,999,930		$	2,052,209
Capital leases		203,417			246,930
Total debt		2,203,347			2,299,139
Less current portion		(213,501	)		(187,771	)
Total long-term debt	$	1,989,846		$	2,111,368

Revolving Credit Facility

     The Company entered into a three-year Credit and Security Agreement, dated June 4, 2007, with Merrill Lynch Capital (now GE Capital) pursuant to which a $10.0 million revolving loan facility was made available to the Company. Obligations under the Credit and Security Agreement are secured by substantially all the assets of the Company excluding the Company’s real property located at its West Bridgewater facility, which is subject to a separate mortgage. The revolving credit facility, which may be used for working capital and other general corporate purposes, is governed by a borrowing base. The loan bears interest at a rate per annum equal to 2.75% over LIBOR. The Company pays 0.50% per annum as an unused line fee. Interest is payable monthly. Amounts under the revolving loan facility may be repaid and re-borrowed until June 4, 2010. Mandatory prepayments of the revolving loan facility are required any time the outstanding revolving loan balance exceeds the borrowing base. The agreement contains standard representations, covenants and events of default for facilities of this type. In addition, the agreement prohibits the payment of dividends during the term of the agreement. Occurrence of an event of default allows the lenders to accelerate the payment of the loans and/or terminate the commitments to lend, in addition to the exercise of other legal remedies, including foreclosing on collateral. As of March 31, 2008, $7.2 million was available for borrowing at an interest rate of 5.45%. There have been no draw downs on the line of credit during the three or six month periods ended March 31, 2008.

Real Property Mortgage Note

     The Company has a promissory note (the “Note”) with Commerce Bank & Trust Company (“Commerce Bank”) which is secured by a mortgage on the real property located at 375 West Street, West Bridgewater, Massachusetts (the “Real Property”). The outstanding principal balance under the Note bears interest at a rate per annum equal to 0.75% in excess of Commerce Bank’s published corporate base rate. The effective interest rate as of March 31, 2008 was 6.00%. The unpaid principal and interest under the Note is due and payable in full on August 31, 2009, although the Note may be repaid in whole or part, at any time, without penalty. The outstanding principal balance under the Note, together with all unpaid interest, may be accelerated and become immediately due and payable following a default under the Note or the loan agreement (and the expiration of applicable cure periods) or if the Real Property is transferred by the Company to a third party without Commerce Bank’s consent.

9. Income Taxes

     The Company adopted the provisions of FIN 48 as of October 1, 2007. The adoption of FIN 48 did not have a material effect on the Company’s condensed financial position, results of operations or cash flows.

10. Rights Offering Issuance Costs

     Rights offering issuance costs were related to the rights offering which occurred in May 2007. The Company initiated the rights offering to raise capital to finance its exit from bankruptcy.

11. Discontinued Operations, Genomics Collaborative

     On March 29, 2007, the Company and BioServe Technologies, LLC (“BioServe”) entered into an asset purchase agreement pursuant to which BioServe agreed to purchase certain assets principally used in the business the Company acquired from Genomics Collaborative and assumed certain limited liabilities of the business. Under the terms of the asset purchase agreement, the consideration consisted of $2.0 million cash, subject to reduction for inventory adjustments, and a 7.5% royalty on BioServe’s net sales related to the business for five years. The assets sold included $0.9 million of fixed assets, certain intangible assets which were fully amortized and its library of specimens which had a carrying amount of $0. The Company recorded a gain on the sale of $0.8 million.

- 9 -

12. Stockholders’ Equity

     The Company is authorized to issue 35,000,000 shares of common stock and 5,000,000 shares of preferred stock at $0.001 par value. The Board of Directors may, without further action by the Company’s shareholders, issue preferred stock in one or more series. These terms may include voting rights, preferences as to dividends and liquidation, and conversion and redemption rights.

     On January 8, 2008 and November 14, 2007, the non-employee directors were issued a total of 1,784 and 1,664 shares of the Company’s common stock, respectively.

     As of March 31, 2008, the total number of shares outstanding was 18,561,396.

     The Company is prohibited from paying dividends under the Credit and Security Agreement with GE Capital.

13. Stock-Based Compensation Plans

     SeraCare has granted various stock-based awards under its Amended and Restated 2001 Stock Incentive Plan (the “Plan”), which are described in further detail in SeraCare’s Annual Report on Form 10-K for the year ended September 30, 2007. Unless the Compensation Committee otherwise provides, stock options vest ratably over three years. The maximum term of stock options is ten years. Options that are granted to Board members generally vest either immediately or over one year. In accordance with SFAS No. 123 (revised 2004), “Share-Based Payments”, compensation cost for stock-based awards recognized during the three and six months ended March 31, 2008 and 2007 was a follows:

	Three Months Ended				Six Months Ended
	March 31				March 31
	2008		2007		2008		2007
Stock options	$	504,697	$	513,325	$	903,005	$	1,102,169

A summary of the Company’s options as of March 31, 2008 and changes during the six months ended is presented below:

				Weighted-
				Average
	Number			Exercise
	of			Price Per
Options	Options			Share
Outstanding September 30, 2007		1,441,500		$	7.57
Granted		490,000		$	5.35
Exercised		—		$	—
Forfeited/Expired		(112,500	)	$	5.22
Outstanding March 31, 2008		1,819,000		$	7.11
Exercisable at March 31, 2008		819,833		$	8.89

          As of March 31, 2008, options to purchase 466,060 shares of common stock remain available for future grants under the Plan.

          As of March 31, 2008, options to purchase 700,000 shares of common stock were issued outside the Plan, of which 233,333 were exercisable. During fiscal 2008, no additional options to purchase shares of common stock were issued outside of the Plan. These options vest in equal annual installments over a period of three years and have a maximum term of ten years.

          During the three and six months ended March 31, 2008, the Company granted 1,784 and 3,448 shares of common stock to the non-employee directors under the Plan respectively. The fair value of which was expensed to selling, general and administrative during the period. The Company recognized the entire expense during the quarter. The Company did not grant any stock options with an exercise price that was less than the market price of the underlying stock on the date of the grant in the current period.

- 10 -

14. Earnings Per Share

     Basic net income (loss) per common share is computed based on the weighted average number of common shares outstanding during the period. Diluted net income (loss) per common share is computed in accordance with the “if converted” method, which uses the weighted average number of common shares outstanding during the period and also includes the dilutive effect of potentially issuable common stock from outstanding stock options and warrants.

     The following table sets out the computations of basic and diluted net income per common share:

	Three Months Ended March 31,						Six Months Ended March 31,
	2008			2007			2008			2007
Numerator:
Net loss from continuing operations	$	(330,651	)	$	(4,124,893	)	$	(997,708	)	$	(6,635,147	)
Income (loss) from discontinued operations, net of income tax		—			207,717			—			(92,480	)
Net Loss	$	(330,651	)	$	(3,917,176	)	$	(997,708	)	$	(6,727,627	)
Denominator:
Weighted average common shares outstanding		18,561,239			14,282,948			18,559,966			14,282,948
Effect of dilutive securities:
Stock options(1)		—			—			—			—
Diluted weighted average common shares outstanding		18,561,239			14,282,948			18,559,966			14,282,948
Basic and diluted net loss per common share:
Continuing operations	$	(0.02	)	$	(0.29	)	$	(0.05	)	$	(0.46	)
Discontinued operations		—			0.02			—			(0.01	)
Net loss	$	(0.02	)	$	(0.27	)	$	(0.05	)	$	(0.47	)

(1) Excluded from the calculation of diluted net loss per common share for the three months ended March 31, 2008 and 2007 were 1,789,522 and 1,603,482 shares, respectively, related to stock options because their effect was anti-dilutive. For the six months ended March 31, 2008 and 2007, 1,680,052 and 1,790,681 shares, respectively, were excluded from the calculation of diluted net loss per common share related to stock options because their effect was anti-dilutive.

15. Segment Information

     The Company’s business is divided into two segments: Diagnostic & Biopharmaceutical Products and BioServices. SeraCare’s Diagnostic & Biopharmaceutical Products segment includes two categories: controls and panels used for the evaluation and quality control of infectious disease tests in hospital and clinical labs, and blood banks, and byin vitro

- 11 -

diagnostic manufacturers; and reagents and bioprocessing products, which include the manufacture and supply of biological materials used in the research, development and manufacturing of human and animal diagnostics, therapeutics and vaccines. The BioServices segment includes biobanking, sample processing and testing services for research and clinical trials, and contract research services in molecular biology, virology and biochemistry. These reportable segments are strategic business lines that offer different products and services and require different marketing strategies.

     The Company utilizes multiple forms of analysis and control to evaluate the performance of the segments and to evaluate investment decisions. Revenue and gross profit are deemed to be the most significant measurement of performance, since administrative expenses are not allocated or reviewed by management at the segment level. Therefore, management has not allocated research and development expense, selling, general and administrative expenses, interest expense or reorganization items to the segments. Amortization of intangibles is not allocated to the segment level and accordingly has not been included in this data. The impact of discontinued operations has also been excluded from the data disclosed here. The following segment financial statements have been prepared on the same basis as the Company’s financial statements.

     The Company’s segment information for the three months and six months ended March 31, 2008 and 2007 is as follows:

	Three Months Ended				Six Months Ended
	March 31,				March 31,
	2008		2007		2008		2007
Revenue:
Diagnostic and Biopharmaceutical Products	$	8,807,984	$	10,808,716	$	17,908,617	$	17,756,810
BioServices		3,722,159		3,180,593		7,247,845		6,142,871
Total revenue	$	12,530,143	$	13,989,309	$	25,156,462	$	23,899,681
Gross Profit:
Diagnostic and Biopharmaceutical Products	$	3,662,185	$	2,861,377	$	6,732,653	$	4,742,400
BioServices		1,050,769		469,961		2,078,784		1,059,322
Total gross profit	$	4,712,954	$	3,331,338	$	8,811,437	$	5,801,722

- 12 -

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

     This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with our Financial Statements and related notes thereto and other financial information included elsewhere in thisForm 10-Q and our Annual Report onForm 10-K for the year ended September 30, 2007.

Business Overview

     SeraCare serves the global life sciences industry by providing vital products and services to facilitate the discovery, development and production of human and animal diagnostics and therapeutics. The Company’s innovative portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers and biobanking and contract research services. SeraCare’s quality systems, scientific expertise and state-of-the-art facilities support its customers in meeting the stringent requirements of the highly regulated life sciences industry.

     The Company’s business is divided into two segments: Diagnostic & Biopharmaceutical Products and BioServices. SeraCare’s Diagnostic & Biopharmaceutical Products segment includes two types of products: controls and panels, which include the manufacture of products used for quality control of infectious disease testing in hospital and clinical testing labs and blood banks, and byin vitrodiagnostic manufacturers; and reagents and bioprocessing products, which include the manufacture and supply of biological materials used in the research, development and manufacturing of human and animal diagnostics, therapeutics and vaccines. The BioServices segment includes biobanking, sample processing and testing services for research and clinical trials, and contract research services in molecular biology, virology, immunology and biochemistry.

Critical Accounting Policies and Estimates

     As previously disclosed in our Annual Report on Form 10-K for the year ended September 30, 2007, we have identified revenue recognition, inventory valuation, valuation of long-lived and intangible assets and goodwill, contingencies and litigation reserves, stock-based compensation, and accounting for income taxes as the accounting policies critical to the operations of SeraCare. For a full discussion of these policies, please refer to our Annual Report on Form 10-K for the year ended September 30, 2007.

Results of Operations

     The following table shows gross profit and expense items as a percentage of net revenue:

	Three Months Ended						Six Months Ended
	March 31,						March 31,
	2008			2007			2008			2007
	%			%			%			%
Revenue		100.0			100.0			100.0			100.0
Cost of revenue		62.4			76.2			65.0			75.7
Gross profit		37.6			23.8			35.0			24.3
Research and development expense		3.3			0.7			3.2			0.8
Selling, general and administrative expenses		32.8			24.2			31.1			28.2
Reorganization items		3.2			26.2			4.0			20.4
Operating loss		(1.7	)		(27.3	)		(3.3	)		(25.1	)
Interest expense		(0.7	)		(1.4	)		(0.8	)		(1.8	)
Interest expense, related parties		—			(0.8	)		—			(1.0	)
Other income (expense), net		—			0.2			0.2			0.3
Loss before income taxes		(2.4	)		(29.3	)		(3.9	)		(27.6	)
Income taxes		0.2			0.2			0.1			0.2
Loss from continuing operations		(2.6	)		(29.5	)		(4.0	)		(27.8	)
Income (loss) from discontinued operations, net of income tax		—			1.5			—			(0.3	)
Net loss		(2.6	)		(28.0	)		(4.0	)		(28.1	)

- 13 -

Comparison of periods ended March 31, 2008 and March 31, 2007

Revenue

     The following table sets forth segment revenue in millions of dollars for the periods ended March 31, 2008 and 2007:

	Three Months Ended							Six Months Ended
	March 31,		March 31,		Percent			March 31,		March 31,		Percent
	2008		2007		Change			2008		2007		Change
Diagnostic and Biopharmaceutical Products	$	8.8	$	10.8		(19	%)	$	17.9	$	17.8		1	%
BioServices		3.7		3.2		16	%		7.3		6.1		20	%
Total revenue	$	12.5	$	14.0		(11	%)	$	25.2	$	23.9		5	%

     Revenue for the three months ended March 31, 2008 decreased by 11%, or $1.5 million, to $12.5 million from $14.0 million in the three months ended March 31, 2007. Diagnostic & Biopharmaceutical Products revenue during the same period decreased by $2.0 million, a 19% decrease, while BioServices revenue increased by $0.5 million, a 16% increase. Diagnostic & Biopharmaceutical Products revenue had nominal sales from therapeutic grade albumin products during the current quarter as compared to $4.4 million in the three months ended March 31, 2007. This revenue has historically been variable and is not expected to be significant during the remainder of the year due to the validation requirements to switch suppliers of raw materials used in biopharmaceutical manufacturing. The Company switched suppliers in December 2007 as its previous supply agreement was not renewed. Excluding therapeutic grade albumin products, our core manufactured products increased $2.4 million, or 38%, due to organic growth. Revenue for our BioServices segment increased $0.5 million in the three months ended March 31, 2008 due to increased testing services to non-government entities. The increase also included $0.2 million billed pursuant to a government contract which related to the settlement of indirect billing rates used in previous periods.

For the six months ended March 31, 2008, revenue increased by 5%, or $1.3 million, to $25.2 million from $23.9 million in the six months ended March 31, 2007. Diagnostic & Biopharmaceutical Products revenue during the same period increased by $0.1 million, a 1% increase, while BioServices revenue increased by $1.2 million, a 20% increase. For the reasons discussed above, Diagnostic & Biopharmaceutical Products revenue included $2.6 million from therapeutic grade albumin products for the first six months of fiscal 2008 as compared to $5.6 million in the six months ended March 31, 2007. Excluding therapeutic grade albumin products, our core manufactured products increased $3.2 million, or 26%, due to organic growth. Revenue for our BioServices segment increased $1.2 million in the six months ended March 31, 2008 due to increased testing services to non-government entities and $0.7 million billed pursuant to government contracts which related to the settlement of indirect billing rates used in previous periods.

Gross Profit

     Gross profit margin increased to $4.7 million, or 37.6% of revenue, for the quarter ended March 31, 2008 from $3.3 million or 23.8% of revenue for the quarter ended March 31, 2007. For the six months ended March 31, 2008, gross profit margin increased to $8.8 million, or 35.0% of revenue, as compared to $5.8 million, or 24.3% of revenue, for the six months ended March 31, 2007. The increase in gross profit was mainly due to the benefit of achieving higher revenue in our core manufactured products, as compared to therapeutic grade albumin products, which have lower margins, and improved margin rates due to increased pricing in fiscal 2008. Our margin rates also benefited by $0.2 million and $0.7 million for the three and six month periods ended March 31, 2008, respectively, from billings pursuant to government contracts which related to the settlement of indirect billing rates used in previous periods.

Research and Development Expense

     Research and development expense totaled $0.4 million, or 3.3% of revenue, and $0.8 million, or 3.2% of revenue, for the three and six month periods ended March 31, 2008 compared to $0.1 million, or 0.7% of revenue, and $0.2 million, or 0.8% of revenue, for the three and six month periods ended March 31, 2007. As part of our strategic plan, we have increased spending on research and development activities in fiscal 2008 as we emphasize the creation of new products and technologies.

- 14 -

Selling, General and Administrative Expenses

     Selling, general and administrative expenses increased to $4.1 million, or 32.8% of revenue, and $7.8 million, or 31.1% of revenue, for the three and six month periods ended March 31, 2008 compared to $3.4 million, or 24.2% of revenue, and $6.7 million, or 28.2% of revenue, for the three and six month periods ended March 31, 2007.These increases primarily reflect the impact of building a new management team and filling positions that were vacant in the first half of fiscal 2007, increased accounting and legal fees and additional marketing expenses associated with the rebranding strategy which was initiated in late fiscal 2007.

Reorganization Items

     Reorganization items include legal, accounting and other professional fees related to our bankruptcy proceedings, reorganization, litigation and efforts to become compliant with the Securities and Exchange Commission (“SEC”). These expenses totaled $0.4 million and $1.0 million for the three and six month periods ended March 31, 2008, respectively, as compared to $3.7 million and $4.9 million for the three and six month periods ended March 31, 2007, respectively.

Operating Loss

     Operating loss resulted from the factors above and included reorganization items as well as stock-based compensation expense. Operating loss was $0.2 million and $0.8 million for the three and six month periods ended March 31, 2008, respectively, which included stock-based compensation expense and reorganization expense totaling $0.9 million and $1.9 million for the three and six month periods ended March 31, 2008, respectively, as compared to operating loss of $3.8 million and $6.0 million for the three and six month periods ended March 31, 2007, respectively, which included stock-based compensation expense and reorganization expense totaling $4.2 million and $6.0 million for the three and six month periods ended March 31, 2007, respectively.

Interest Expense

     Interest expense totaled $0.1 million and $0.2 million for the three and six month periods ended March 31, 2008, respectively, as compared to $0.2 million and $0.5 million for the three and six month periods ended March 31, 2007, respectively. The decrease in interest expense is due to a lower level of borrowed funds in fiscal 2008 compared to the same period in fiscal 2007 resulting from repayment of a portion of long-term debt in the first quarter of fiscal 2007 and full repayment of the then-existing senior debt commitments in May 2007. Interest expense to related parties totaled $0.1 million and $0.2 million for the three and six month periods ended March 31, 2007, respectively. Notes payable to related parties were repaid in full in May 2007.

Net Loss from Continuing Operations

     As a result of the above, net loss from continuing operations was $0.3 million and $1.0 million for the three and six month periods ended March 31, 2008, respectively, as compared to $4.1 million and $6.6 million for the three and six month periods ended March 31, 2007, respectively.

Income (loss) from Discontinued Operations

     Income (loss) from discontinued operations was generated by the Genomics Collaborative division of the business which was sold in March 2007. Income related to that division totaled $0.2 million in the three months ended March 31, 2007, which included a gain on the sale of $0.8 million. The division generated losses of $0.1 million for the six months ended March 31, 2007.

Net Loss and Net Loss Per Share

     Net loss was $0.3 million and $1.0 million for the three and six month periods ended March 31, 2008, respectively, as compared to a net loss of $3.9 million and $6.7 million for the three and six month periods ended March 31, 2007, respectively. Net loss per share on a basic and diluted basis was $0.02 and $0.05 for the three and six month periods ended March 31, 2008, respectively, as compared to $0.27 and $0.47 for the three and six month periods ended March 31, 2007, respectively.

- 15 -

Liquidity and Capital Resources

Cash Flows

     The following table summarizes our sources and uses of cash over the six month periods indicated (in millions):

	March 31,			March 31,
	2008			2007
Net cash used in operating activities	$	(1.9	)	$	(1.2	)
Net cash (used in) provided by investing activities		(1.5	)		1.8
Net cash used in financing activities		(0.1	)		(5.2	)
Net decrease in cash and cash equivalents	$	(3.5	)	$	(4.6	)

     As of March 31, 2008, our cash balance was $6.0 million, a decline of $3.5 million from our cash balance as of September 30, 2007. During the first six months of fiscal 2008, we had a net loss of $1.0 million, which included non-cash charges of approximately $2.7 million, primarily related to depreciation and amortization, inventory write-downs and stock based compensation charges. We experienced increases in accounts receivable and inventory of $1.4 million and $4.6 million, respectively, reducing our cash balances. We had an increase in accounts payable of $2.3 million. The increase in accounts receivable is primarily due to strong sales during the period and a low accounts receivable balance at the beginning of fiscal 2008 due to accelerated cash collections at the end of fiscal 2007. The increase in inventory relates primarily to a build-up of inventory due to the increase in customer demand for our core manufactured products and in preparation for the move of our manufacturing operations from West Bridgewater, Massachusetts to Milford, Massachusetts. The increase was also impacted by the purchase of scarce materials for which there is limited supply in the market. Accounts payable increased during the period due to the increase in inventory and the timing of payments. Other sources and uses of cash include $2.7 million in capital expenditures, primarily related to the construction in Milford, Massachusetts and reimbursement of tenant improvement costs of $1.2 million. We recorded the landlord reimbursement of $1.2 million as a deferred lease liability which is recognized over the term of the lease using the straight-line method. As such, our other liabilities increased to $1.7 million as of March 31, 2008.

     We had a current ratio of 3.6 to 1 as of March 31, 2008 compared to 4.7 to 1 as of September 30, 2007. Total liabilities as of March 31, 2008 were $11.2 million compared to $7.9 million as of September 30, 2007. The total debt to equity ratio as of March 31, 2008 was 0.04 compared to 0.05 as of September 30, 2007.

     We believe our current cash on hand and future operating cash flows will be sufficient to meet our future operating cash needs in fiscal 2008. Furthermore, our availability under our Credit and Security Agreement with GE Capital provides an additional source of liquidity should it be required.

Operating Cash Flows

     Cash used in operating activities was $1.9 million for the six months ended March 31, 2008 an increase of $0.7 million compared to cash used of $1.2 million for the six months ended March 31, 2007. Changes in cash flows from operations are driven by the items discussed above, including building inventory and an increase in accounts receivable. In addition, bankruptcy accruals increased during the six months ended March 31, 2007 due to the approval of the Plan of Reorganization.

Investing Cash Flows

     Cash used in investing activities was $1.5 million in the six months ended March 31, 2008, an increase in cash used in investing activities of approximately $3.3 million compared to cash provided by investing activities of $1.8 million in the six months ended March 31, 2007. Cash used in investing activities in the six months ended March 31, 2008 relate primarily to capital expenditures for construction of our new corporate offices in Milford, Massachusetts, net of landlord reimbursements. During the six months ended March 31, 2007, the Company received $2.0 million for the sale of its Genomics Collaborative division. In addition, the Company was operating under Chapter 11 of the United States Bankruptcy Code during the six months ended March 31, 2007, which limited our ability to invest in capital expenditures for the future growth of the Company.

Financing Cash Flows

     Cash used in financing activities was $0.1 million in the six months ended March 31, 2008 compared to cash used of $5.2 million in the six months ended March 31, 2007. During the first six months of fiscal 2007, the Company paid down $4.6 million in long-term debt and incurred $0.6 million in issuance costs related to the Rights Offering.

- 16 -

Off-Balance Sheet Arrangements

     During the first six months of fiscal 2008 and 2007, we were not party to any off-balance sheet arrangements.

Contractual Obligations and Commitments

     In addition to the items described in the Company’s Form 10-K for the year ended September 30, 2007, the Company entered into a lease agreement on October 1, 2007 pursuant to which we are leasing approximately 60,000 rentable square feet in three buildings in a business park in Milford, Massachusetts. The initial term of the lease agreement is approximately ten years, which may be extended by us for three successive extension terms of five years each, subject to certain conditions set forth in the lease agreement. The new campus expands upon space currently occupied by SeraCare at the Milford site. Renovations on the buildings in the new Milford facility began in early October 2007. In January 2008, we moved our headquarters from our West Bridgewater facility to our Milford facility. The Milford facility will house our entire Massachusetts operations of approximately 140 employees, including our corporate headquarters. The total rental obligation under this lease is $8.9 million. The renovations to the Milford facility will generate an increase in capital expenditures related to leasehold improvements net of a $1.2 million landlord allowance in fiscal 2008.

Assets Held for Sale

As a result of signing the lease agreement described above, we began marketing the West Bridgewater facility and land for sale. The net book value of these assets is $1.9 million as of March 31, 2008 and is classified as Assets held for sale on the accompanying March 31, 2008 Balance Sheet.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

     Interest Rate and Market Risk.As of March 31, 2008, our only assets or liabilities subject to risks from interest rate changes are (i) debt under the West Bridgewater mortgage note in the aggregate amount of $2.0 million and (ii) cash and cash equivalents of $6.0 million, substantially all of which are collateralized by short-term federal government securities. Our mortgage debt bears interest at a variable rate. If interest rates affecting the Company’s floating rate long-term debt were to change by one percentage point from levels at March 31, 2008, we estimate that the fair value of that debt will change by an immaterial amount, and therefore, our exposure to interest rate changes is immaterial.

     Foreign Currency Exchange Risk.The Company does not believe that it currently has material exposure to foreign currency exchange risk because all international sales are designated in U.S. dollars.

     We were not a party to any derivative financial instruments at March 31, 2008.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

     Rule 13a-15(b) under the Exchange Act and Item 307 of Regulation S-K require management to evaluate the effectiveness of the design and operation of our disclosure controls and procedures as of the end of each fiscal quarter. Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed under the Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

     The Company’s management, including the principal executive officer and the principal financial officer, conducted an evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q of the effectiveness of the design and operation of the Company’s disclosure controls and procedures. Based on that evaluation, the Company’s principal executive officer and principal financial officer concluded that the Company’s disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2008.

     As noted in Item 4 of the Company’s Form 10-Q for the quarter ended June 30, 2007, the Company spent significant resources on completing its financial statements and obtaining audits for fiscal years 2005, 2006 and 2007, which negatively impacted the Company’s ability to timely file the Form 10-Q for that quarter. The Company’s Audit Committee also received a draft letter during the quarter ended March 31, 2008 from Mayer Hoffman McCann P.C. which noted resource issues with staffing and accumulating documentation associated with the challenges and volume of work and information necessary to accurately complete three years of financial statements and audits that were required for the September 30, 2007 Form 10-K.

Changes in Internal Control

     As required by Rule 13a-15(d) of the Exchange Act, the Company’s management, including the principal executive officer and the principal financial officer conducted an evaluation of the internal control over financial reporting to determine whether any changes occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting. Based on that evaluation, the principal executive officer and the principal financial officer concluded no such changes during the quarter ended March 31, 2008 materially affected, or were reasonably likely to materially affect, the Company’s internal control over financial reporting.

- 17 -

PART II: OTHER INFORMATION

Item 1. Legal Proceedings

     With respect to the fiscal quarter ended March 31, 2008, the information required in response to this Item is set forth in Note 5 to our Financial Statements contained in this report, and such information is hereby incorporated herein by reference. Such description contains all of the information required with respect hereto.

Item 1A. Risk Factors

     There were no material changes from the risk factors previously disclosed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended September 30, 2007.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

     Set forth below is information regarding shares of common stock issued, and options granted, by us during the quarter ended March 31, 2008 that were not registered under the Securities Act of 1933 (the “Securities Act”). Also included is the consideration, if any, we received for such shares and options.

          1. On March 10, 2008 the Company granted an option to Michael Steele to purchase 40,000 shares of the Company’s common stock at an exercise price of $5.00 per share.

          2. On January 8, 2008, each of the four non-employee directors received 446 shares of the Company’s common stock.

     No general solicitation was made in the United States by us or any person acting on our behalf; the securities were sold pursuant to Section 4(2) under the Securities Act and are subject to transfer restrictions; and certificates for the shares contain appropriate legends stating that such securities have not been registered under the Securities Act and may not be offered or sold absent registration or pursuant to an exemption therefrom.

Item 4. Submission of Matters to a Vote of Securities Holders

     We held our annual meeting of stockholders on February 27, 2008 in Milford, MA. Each of our directors: Eugene I. Davis, Samual D. Anderson, Sarah L. Murphy, Jill Tillman, and Susan L.N. Vogt were elected to continue to serve for a one-year term and until their successors are duly elected and qualified for their earlier resignation or removal. An amendment and restatement of our Amended and Restated 2001 Stock Incentive Plan was also approved.

     The number of votes cast for, against, or withheld, as well as the number of abstentions and broker non-votes as to each such matter are as follows:

          1. Election of Directors

	Number of		Number of
Nominee	Votes For		Votes Withheld
Susan L. N. Vogt		16,581,254		309,644
Eugene I. Davis		14,186,159		2,704,739
Samuel D. Anderson		15,318,124		1,572,774
Sarah L. Murphy		14,403,433		2,487,465
Jill Tillman		14,403,766		2,487,132

          2. Amendment and Restatement of our Amended and Restated 2001 Stock Incentive Plan

FOR	AGAINST	ABSTAIN
10,705,374	1,794,391	291,702

- 18 -

Item 6. Exhibits

(a)Exhibits.

     The Exhibits listed in the Exhibit Index immediately preceding the Exhibits are filed as a part of this Quarterly Report on Form 10-Q.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SERACARE LIFE SCIENCES, INC.
		/s/ Gregory A. Gould
	By:	Gregory A. Gould
	Title:	Chief Financial Officer, Treasurer
		and Secretary
Date: May 15, 2008

- 19 -

INDEX TO EXHIBITS

Exhibit
Number		Exhibit Description
	10.1	Amended and Restated 2001 Stock Incentive Plan
	31.1	Sarbanes-Oxley Act Section 302 Certification of Susan L.N. Vogt.
	31.2	Sarbanes-Oxley Act Section 302 Certification of Gregory A. Gould.
	32.1	Sarbanes-Oxley Act Section 906 Certification of Susan L.N. Vogt and Gregory A. Gould.

- 20 -